Lucid Diagnostics

Lucid Diagnostics EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Lucid Diagnostics (LUCD) as of Oct 18, 2026 is -49.64 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -44.89 M USD — a change of 10.59% (lower).

EBITDA

-49.64 MUSD

YoY

10.59%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Lucid Diagnostics is 2025 -49.64 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Lucid Diagnostics was 2024 -44.89 M USD. It decreases by 10.59% lower compared to the previous year.

The Lucid Diagnostics EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-1.13 M USD
Jan 1, 2019
-4.42 M USD
Jan 1, 2020
-8.28 M USD
Jan 1, 2021
-27.42 M USD
Jan 1, 2022
-54.22 M USD
Jan 1, 2023
-49.75 M USD
Jan 1, 2024
-44.89 M USD
Jan 1, 2025
-49.64 M USD
The Lucid Diagnostics EBITDA history
YEAREBITDAYoY
-49.64 MUSD+10.59%
-44.89 MUSD-9.78%
-49.75 MUSD-8.25%
-54.22 MUSD+97.76%
-27.42 MUSD+231.17%
-8.28 MUSD+87.30%
-4.42 MUSD+292.59%
-1.13 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Lucid Diagnostics Stock analysis

What does Lucid Diagnostics do? Lucid Diagnostics Inc, headquartered in New York City, is a commercial-stage medical diagnostics technology company focused on gastroesophageal reflux disease (GERD) and esophageal cancer prevention. The company, listed on October 14, 2021, employs 82 full-time staff and offers EsoCheck, a noninvasive capsule device for esophageal cell sampling, and EsoGuard, a DNA assay for detecting precancerous conditions. It is developing EsoCure, an ablation device for treating dysplastic Barrett's esophagus to prevent progression to lethal esophageal adenocarcinoma (EAC). Lucid Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lucid Diagnostics stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Lucid Diagnostics is -49.64 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Lucid Diagnostics changed from -44.89 M USD to -49.64 M USD, representing a 10.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Lucid Diagnostics since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Lucid Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Lucid Diagnostics

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Lucid Diagnostics